Biogen (NASDAQ:BIIB) Downgraded to Strong Sell Rating by Zacks Research

Biogen (NASDAQ:BIIB) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other equities research analysts have also weighed in on BIIB. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd. Weiss Ratings raised Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Royal Bank Of Canada lifted their target price on shares of Biogen from $222.00 to $227.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 27th. The Goldman Sachs Group increased their price target on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Finally, Piper Sandler restated an “overweight” rating and issued a $225.00 price objective (up from $214.00) on shares of Biogen in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $217.41.

Biogen Trading Down 0.3%

Shares of BIIB opened at $216.06 on Monday. The firm has a market cap of $31.90 billion, a price-to-earnings ratio of 23.18 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen has a fifty-two week low of $121.05 and a fifty-two week high of $219.72. The firm has a 50 day moving average price of $194.96 and a 200-day moving average price of $186.27.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts forecast that Biogen will post 13.95 earnings per share for the current year.

Institutional Investors Weigh In On Biogen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Reflection Asset Management bought a new position in Biogen in the fourth quarter worth $25,000. WPG Advisers LLC boosted its holdings in shares of Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. First Horizon Corp purchased a new stake in shares of Biogen in the 4th quarter worth about $30,000. WFA of San Diego LLC purchased a new stake in shares of Biogen in the 2nd quarter worth about $32,000. Finally, Root Financial Partners LLC increased its stake in shares of Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Needham raised its price target on Biogen to $256 and reiterated a Buy rating, citing stronger-than-expected Spinraza HD momentum and progress across the company’s pipeline. Biogen: Key Takeaways From Needham’s Meeting With Top Management
• Positive Sentiment: Biogen said it will showcase new Alzheimer’s disease data at AAIC 2026, including Phase 2 CELIA results for diranersen and additional lecanemab analyses, which could reinforce confidence in one of its key growth areas. Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026
• Positive Sentiment: Biogen was highlighted alongside other biotech leaders hitting new 52-week highs, reflecting broader sector strength and momentum in the stock. Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
• Neutral Sentiment: Zacks added Biogen-related ticker BBIB to its Strong Sell list, but this appears to be a separate ticker and not a direct negative on Biogen Inc. itself. New Strong Sell Stocks for June 30th
• Negative Sentiment: One report said Biogen is trimming Apellis-related R&D spending and pausing or ending investment in most legacy programs after its acquisition, which may raise integration and capital-allocation concerns. Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
• Negative Sentiment: Biogen was also mentioned in a class action settlement notice, which could keep some legal overhang on the shares, though the announcement itself is not a new operational setback. Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.